Proton Boost in Prostate Cancer
Key facts
- Where
- Cincinnati, Egyesült ÁllamokSee the site
Where in Egyesült Államok
- University of CincinnatiCincinnati, Egyesült ÁllamokNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Cincinnati
- Trial code
- NCT03564275
- Record updated
- 2025. május 31.
- Original description
This study uses photon radiation with a proton boost to treat prostate cancer. The purpose of this study is to determine if proton therapy as a boost following photon intensity modulated radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT alone in the treatment of prostate cancer. Our secondary objective is to determine the effectiveness of this treatment regimen. Effectiveness will be determined by length of time to progression or recurrence of disease and overall survival. Patients on this study will be treated with a course of photon radiation therapy followed by a boost course of proton radiation.Read full original descriptionShow less
Assessing the Effectiveness of Photon Therapy With a Proton Therapy Boost in the Treatment of Prostate Cancer as Compared to Photon Therapy Alone
This study uses photon radiation with a proton boost to treat prostate cancer. The purpose of this study is to determine if proton therapy as a boost following photon intensity modulated radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT alone in the treatment of prostate cancer. Our secondary objective is to determine the effectiveness of this treatment regimen. Effectiveness will be determined by length of time to progression or recurrence of disease and overall survival. Patients on this study will be treated with a course of photon radiation therapy followed by a boost course of proton radiation.
Inclusion: ≥18 years of age; Diagnosis of low risk prostate cancer (T1c-T2a, Gleason 6, Prostate Specific Antigen (PSA) <10) -OR-; Diagnosis of intermediate risk prostate cancer (T1c-T2c, Gleason 7 and/or PSA 10- 20); Life expectancy >10 yrs; Physically and mentally capable of signing the consent form of their own volition.
Exclusion: Current or historical use of androgen deprivation therapy; Diagnosis of high risk prostate cancer (T3 or higher, Gleason >7 and/or PSA >20); Previous cancer excluding non-melanoma skin cancer; History of prostatectomy; History of brachytherapy for prostate cancer; < 18 years of age; Life expectancy <10 yrs; Nodal positivity; Physically or mentally incapable of signing the consent form of their own volition.